Pfizer ended development of Phase 1 ulcerative colitis candidate PF‑07899895 in a business‑driven cut, pausing the company’s early‑stage presence in that inflammatory indication. Separately, Tiziana Life Sciences said it will spin its IL‑6 pathway candidate into a new company, citing Big Pharma interest in the modality. The moves underscore active portfolio rebalancing across large and small biopharma: Pfizer is shedding lower‑priority early assets while smaller firms like Tiziana are creating focused vehicles to attract partners or buyers for programs targeting high‑value pathways such as IL‑6.